Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10374335" target="_blank" >RIV/00216208:11140/18:10374335 - isvavai.cz</a>

Alternative codes found

RIV/00669806:_____/18:10374335

Result on the web

<a href="http://dx.doi.org/10.1111/hiv.12581" target="_blank" >http://dx.doi.org/10.1111/hiv.12581</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1111/hiv.12581" target="_blank" >10.1111/hiv.12581</a>

Result language

angličtina

Original language name

Long-term effectiveness of recommended boosted protease inhibitor-based antiretroviral therapy in Europe

Original language description

ObjectivesThe aim of the study was to evaluate the long-term response to antiretroviral treatment (ART) based on atazanavir/ritonavir (ATZ/r)-, darunavir/ritonavir (DRV/r)-, and lopinavir/ritonavir (LPV/r)-containing regimens. MethodsData were analysed for 5678 EuroSIDA-enrolled patients starting a DRV/r-, ATZ/r- or LPV/r-containing regimen between 1 January 2000 and 30 June 2013. Separate analyses were performed for the following subgroups of patients: (1) ART-naive subjects (8%) at ritonavir-boosted protease inhibitor (PI/r) initiation; (2) ART-experienced individuals (44%) initiating the new PI/r with a viral load (VL) 500 HIV-1 RNA copies/mL; and (3) ART-experienced patients (48%) initiating the new PI/r with a VL &gt;500 copies/mL. Virological failure (VF) was defined as two consecutive VL measurements &gt;200 copies/mL 24 weeks after PI/r initiation. Kaplan-Meier and multivariable Cox models were used to compare risks of failure by PI/r-based regimen. The main analysis was performed with intention-to-treat (ITT) ignoring treatment switches. ResultsThe time to VF favoured DRV/r over ATZ/r, and both were superior to LPV/r (log-rank test; P &lt; 0.02) in all analyses. Nevertheless, the risk of VF in ART-naive patients was similar regardless of the PI/r initiated after controlling for potential confounders. The risk of VF in both treatment-experienced groups was lower for DRV/r than for ATZ/r, which, in turn, was lower than for LPV/r-based ART. ConclusionsAlthough confounding by indication and calendar year cannot be completely ruled out, in ART-experienced subjects the long-term effectiveness of DRV/r-containing regimens appears to be greater than that of ATZ/r and LPV/r.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30303 - Infectious Diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2018

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

HIV Medicine

ISSN

1464-2662

e-ISSN

—

Volume of the periodical

19

Issue of the periodical within the volume

5

Country of publishing house

GB - UNITED KINGDOM

Number of pages

15

Pages from-to

324-338

UT code for WoS article

000430107500005

EID of the result in the Scopus database

2-s2.0-85041304540